BCRX
Price
$8.32
Change
-$0.15 (-1.77%)
Updated
Aug 29, 02:20 PM (EDT)
Capitalization
1.78B
61 days until earnings call
HOWL
Price
$1.39
Change
+$0.06 (+4.51%)
Updated
Aug 28 closing price
Capitalization
63.56M
69 days until earnings call
Interact to see
Advertisement

BCRX vs HOWL

Header iconBCRX vs HOWL Comparison
Open Charts BCRX vs HOWLBanner chart's image
BioCryst Pharmaceuticals
Price$8.32
Change-$0.15 (-1.77%)
Volume$100
Capitalization1.78B
Werewolf Therapeutics
Price$1.39
Change+$0.06 (+4.51%)
Volume$91.17K
Capitalization63.56M
BCRX vs HOWL Comparison Chart in %
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HOWL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCRX vs. HOWL commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and HOWL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (BCRX: $8.47 vs. HOWL: $1.39)
Brand notoriety: BCRX: Notable vs. HOWL: Not notable
BCRX represents the Pharmaceuticals: Generic, while HOWL is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 57% vs. HOWL: 27%
Market capitalization -- BCRX: $1.78B vs. HOWL: $63.56M
BCRX [@Pharmaceuticals: Generic] is valued at $1.78B. HOWL’s [@Biotechnology] market capitalization is $63.56M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileHOWL’s FA Score has 1 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • HOWL’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCRX and HOWL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while HOWL’s TA Score has 6 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 3 bearish.
  • HOWL’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, HOWL is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Pharmaceuticals: Generic) experienced а +1.07% price change this week, while HOWL (@Biotechnology) price change was +8.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.18%. For the same industry, the average monthly price growth was +68.08%, and the average quarterly price growth was +82.04%.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.15%. For the same industry, the average monthly price growth was +15.07%, and the average quarterly price growth was +29.12%.

Reported Earning Dates

BCRX is expected to report earnings on Oct 29, 2025.

HOWL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.18% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (-1.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.78B) has a higher market cap than HOWL($63.6M). BCRX YTD gains are higher at: 12.633 vs. HOWL (-6.081). BCRX has higher annual earnings (EBITDA): 63.4M vs. HOWL (-66.34M). BCRX has more cash in the bank: 260M vs. HOWL (77.6M). HOWL has less debt than BCRX: HOWL (37.1M) vs BCRX (703M). BCRX has higher revenues than HOWL: BCRX (558M) vs HOWL (0).
BCRXHOWLBCRX / HOWL
Capitalization1.78B63.6M2,796%
EBITDA63.4M-66.34M-96%
Gain YTD12.633-6.081-208%
P/E RatioN/AN/A-
Revenue558M0-
Total Cash260M77.6M335%
Total Debt703M37.1M1,895%
FUNDAMENTALS RATINGS
BCRX: Fundamental Ratings
BCRX
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
79
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCRXHOWL
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
75%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 17 days ago
79%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
72%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HOWL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGCJX15.720.09
+0.54%
Baillie Gifford EAFE Plus All Cap 3
HGISX59.86N/A
N/A
Hartford Core Equity R4
MBCSX26.17N/A
N/A
MassMutual Blue Chip Growth R5
PLAAX16.43N/A
N/A
PACE Large Co Growth Equity A
FEMAX11.99N/A
N/A
First Eagle U.S. SMID Cap Opportunity A

HOWL and

Correlation & Price change

A.I.dvisor indicates that over the last year, HOWL has been loosely correlated with GNPX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if HOWL jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HOWL
1D Price
Change %
HOWL100%
+4.51%
GNPX - HOWL
41%
Loosely correlated
+1.16%
IPSC - HOWL
41%
Loosely correlated
-2.91%
ATNM - HOWL
40%
Loosely correlated
-1.14%
SYRE - HOWL
39%
Loosely correlated
-2.45%
BCRX - HOWL
38%
Loosely correlated
-0.59%
More